AASLD News

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that COVID-19 coagulation impairment, driven in part by endothelial Factor VIII, is associated with liver injury in infected patients.

Today the American Association for the Study of Liver Diseases (AASLD) announced that Hepatology Communications – AASLD’s free, open-access journal – has been accepted into Clarivate’s Science Citation Index Expanded (SCIE) and Journal Citation Reports – one of the leading citation indexes for journals of science and technology. The journal will now be eligible for an Impact Factor (IF) evaluation

Join me and the AASLD in congratulating Drs. Harvey J. Alter, Michael Houghton, and Charles M. Rice, the 2020 recipients of the Nobel Prize in Physiology for Medicine. Their groundbreaking research identified the Hepatitis C virus (HCV) – a bloodborne pathogen that causes acute and chronic hepatitis, cirrhosis, and liver cancer – and laid the foundation for the future development of a cure.

Alexandria, VA – The American Association for the Study of Liver Diseases (AASLD) Foundation, the largest private supporter of liver disease research and training in the United States, today announced its combined investment of over $2.2 million in Research and Career Development Awards, Abstract Awards, and its Emerging Liver Scholars (ELS) Program. The 2020 award recipients — selected from a

Dear Colleagues: The United States is experiencing the tragic consequences of racism. As health care providers, we have dedicated our lives to caring for our fellow human beings. Therefore, we are compelled to speak out against any treatment that results in unacceptable disparities that marginalize the vulnerable among us. As leaders of the four GI societies, AASLD, ACG, AGA, and ASGE, we stand

The American Association for the Study of Liver Disease (AASLD) has released a clinical insight document for clinicians and frontline healthcare providers who are treating patients with liver disease during the COVID-19 pandemic.

The situation involving the COVID-19 pandemic continues to evolve. There is recent evidence suggesting the potential for coronavirus transmission through droplets and perhaps fecal shedding posing potential risks during endoscopy and colonoscopy to other patients, endoscopy personnel, and ourselves.

Hepatology Communications , AASLD’s online Open Access journal, is seeking candidates who are interested in a year-long Editorial Fellowship. Download the Editorial Fellowship description . Each candidate should submit the following documents to Olivia Potvin at opotvin@bidmc.harvard.edu by December 31, 2020.

The American Association for the Study of Liver Diseases (AASLD) has appointed Matthew R. D’Uva, FASAE, CAE, as its new chief executive officer, effective January 21, 2020.

Media Contact: Caroline Laurin Phone: (703) 299-9766 Onsite phone: (415)-978-3601 Email: media@aasld.org San Francisco – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that African-American patients on waitlists for liver transplantation, despite severe disease and high scores for prioritization

ata from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that combination therapy with direct-acting antivirals (DAAs) and ezetimibe─ a cholesterol medication that has also been shown to block the entry of hepatitis C (or HCV) into the bloodstream of uninfected people ─ given immediately before and seven days after

Four societies focused on liver disease research and treatment announced a global call-to-action initiative to simplify hepatitis C testing and treatment. The societies, in partnership with the Clinton Health Access Initiative (CHAI), launched the initiative at The Liver Meeting® – held by the American Association for the Study of Liver Diseases.

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that a machine-learning tool could successfully predict the risk of having non-alcoholic steatohepatitis (NASH) among patients with co-existing diseases.

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that hepatitis C virus-related hepatocellular carcinoma (HCC) patients who achieved sustained virologic response (SVR) – denoting an undetectable level of HCV virus - with any oral direct-acting antiviral (DAA) had over 60-70 percent improvement in five-year